Course Information

Release date: August 10, 2026
Expiration date: August 10, 2027
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This educational activity is supported by medical education grants from Incyte Corporation and Novartis Pharmaceuticals Corporation.

PROGRAM OVERVIEW

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that remains underrecognized and undertreated despite significant disease burden and prolonged diagnostic delays. At the same time, the HS therapeutic landscape is rapidly evolving, with emerging targeted therapies reshaping the understanding of inflammatory pathway-driven disease management.

This interactive educational activity will explore the immunopathogenesis of HS, differentiate key inflammatory pathways including interleukin (IL)-17 and Janus kinase (JAK)-STAT signaling, and review pivotal and emerging clinical trial data supporting current and investigational targeted therapies in moderate-to-severe HS.

Learning Objectives

TARGET AUDIENCE

This activity is designed for dermatologists and dermatology-focused advanced practice providers who care for patients with HS.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Describe the inflammatory pathways that drive HS pathogenesis
Differentiate the mechanisms of action of current and investigational targeted therapies for HS
Interpret key efficacy and safety findings from clinical trials evaluating targeted therapies for HS

Faculty Information and Disclosures

FACULTY

Christopher J. Haas, MD, FAAD

Assistant Professor
Medical Student Clerkship Director
Residency Program Director
University Medical Center Site Director
Louisiana State University Health Sciences Center
New Orleans, Louisiana

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

Christopher J. Haas, MD, FAAD
Speaker Bureaus: AbbVie, Leo, UCB

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 10, 2026, to August 10, 2027, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required

For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: August 10, 2026Expiration date: August 10, 2027Estimated time to complete activity: 45 minutes

Decoding the Pathways of Hidradenitis Suppurativa: An Interactive MOA Challenge on Emerging Targeted Therapies